Immunohistochemical Classification of Primary and Secondary Glioblastomas

Overview

Journal Korean J Pathol

Specialty Pathology

Date 2014 Jan 15

PMID 24421847

Citations 10

Authors

Kyu Sang Lee

Gheeyoung Choe

Kyung Han Nam

An Na Seo

Sumi Yun

Kyung Ju Kim

Hwa Jin Cho

Sung Hye Park

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastomas may develop de novo (primary glioblastomas, P-GBLs) or through progression from lower-grade astrocytomas (secondary glioblastomas, S-GBLs). The aim of this study was to compare the immunohistochemical classification of glioblastomas with clinically determined P-GBLs and S-GBLs to identify the best combination of antibodies for immunohistochemical classification.

Methods: We evaluated the immunohistochemical expression of epidermal growth factor receptor (EGFR), p53, and isocitrate dehydrogenase 1 (IDH-1) in 150 glioblastoma cases.

Results: According to clinical history, the glioblastomas analyzed in this study consisted of 146 P-GBLs and 4 S-GBLs. Immunohistochemical expression of EGFR, p53, and IDH-1 was observed in 62.6%, 49.3%, and 11.1%, respectively. Immunohistochemical profiles of EGFR(+)/p53(-), IDH-1(-)/EGFR(+)/p53(-), and EGFR(-)/p53(+) were noted in 41.3%, 40.2%, and 28.7%, respectively. Expression of IDH-1 and EGFR(-)/p53(+) was positively correlated with young age. The typical immunohistochemical features of S-GBLs comprised IDH-1(+)/EGFR(-)/p53(+), and were noted in 3.6% of clinically P-GBLs. The combination of IDH-1(-) or EGFR(+) was the best set of immunohistochemical stains for identifying P-GBLs, whereas the combination of IDH-1(+) and EGFR(-) was best for identifying S-GBLs.

Conclusions: We recommend a combination of IDH-1 and EGFR for immunohistochemical classification of glioblastomas. We expect our results to be useful for determining treatment strategies for glioblastoma patients.

Citing Articles

Cutaneous Melanoma and Glioblastoma Multiforme Association-Case Presentation and Literature Review.

Orzan O, Giurcaneanu C, Dima B, Dima M, Ion A, Balaceanu B Diagnostics (Basel). 2023; 13(6).

PMID: 36980355 PMC: 10047677. DOI: 10.3390/diagnostics13061046.

THE SAFETY AND EFFICACY OF ROBOT-ASSISTED STEREOTACTIC BIOPSY FOR BRAIN GLIOMA: EARLIEST INSTITUTIONAL EXPERIENCES AND EVALUATION OF LITERATURE.

Rotim K, Splavski B, Vrban F Acta Clin Croat. 2021; 60(2):296-303.

PMID: 34744281 PMC: 8564848. DOI: 10.20471/acc.2021.60.02.17.

Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience.

Mohammadi H, Shiue K, Grass G, Verma V, Engellandt K, Daubner D Neurooncol Pract. 2020; 7(2):185-195.

PMID: 32626587 PMC: 7318854. DOI: 10.1093/nop/npz050.

Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients.

Abdulghani M, Abbas M, Mohammed W Open Access Maced J Med Sci. 2020; 7(21):3514-3520.

PMID: 32010368 PMC: 6986536. DOI: 10.3889/oamjms.2019.751.

Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.

Pirlog R, Susman S, Iuga C, Florian S Medicina (Kaunas). 2019; 55(8).

PMID: 31357616 PMC: 6722920. DOI: 10.3390/medicina55080412.

References

Rong Y, Belozerov V, Tucker-Burden C, Chen G, Durden D, Olson J . Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009; 69(6):2540-9. PMC: 2759716. DOI: 10.1158/0008-5472.CAN-08-1547. View

Lee H, Xu X, Kim H, Jin Y, Sun P, Kim J . Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase.... Korean J Pathol. 2013; 47(1):52-60. PMC: 3589609. DOI: 10.4132/KoreanJPathol.2013.47.1.52. View

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6):597-602. DOI: 10.1007/s00401-008-0455-2. View

Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P . Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology. 2010; 30(4):392-400. DOI: 10.1111/j.1440-1789.2009.01081.x. View

Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y . Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009; 100(10):1996-8. PMC: 11159618. DOI: 10.1111/j.1349-7006.2009.01270.x. View

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G . IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011; 105(2):345-57. DOI: 10.1007/s11060-011-0596-3. View

Choe G, Horvath S, Cloughesy T, Crosby K, Seligson D, Palotie A . Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003; 63(11):2742-6. View

Srividya M, Thota B, Arivazhagan A, Thennarasu K, Balasubramaniam A, Chandramouli B . Age-dependent prognostic effects of EGFR/p53 alterations in glioblastoma: study on a prospective cohort of 140 uniformly treated adult patients. J Clin Pathol. 2010; 63(8):687-91. DOI: 10.1136/jcp.2009.074898. View

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

10.

Stoczynska-Fidelus E, Witusik-Perkowska M, Banaszczyk M, Bienkowski M, Szybka M, Piaskowski S . Glioblastoma specimens with TP53 mutations do not show EGFRvIII amplification. Cancer Genet. 2011; 204(5):282-3. DOI: 10.1016/j.cancergen.2011.03.005. View

11.

Hwangbo W, Lee J, Ahn S, Kim S, Park K, Kim C . EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast. Korean J Pathol. 2013; 47(2):107-15. PMC: 3647122. DOI: 10.4132/KoreanJPathol.2013.47.2.107. View

12.

Mischel P, Cloughesy T, Nelson S . DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004; 5(10):782-92. DOI: 10.1038/nrn1518. View

13.

Deimling A, von Ammon K, Schoenfeld D, Wiestler O, Seizinger B, Louis D . Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 1993; 3(1):19-26. DOI: 10.1111/j.1750-3639.1993.tb00721.x. View

14.

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P . Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64(19):6892-9. DOI: 10.1158/0008-5472.CAN-04-1337. View

15.

Haas-Kogan D, Prados M, Tihan T, Eberhard D, Jelluma N, Arvold N . Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005; 97(12):880-7. DOI: 10.1093/jnci/dji161. View

16.

Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S . p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol. 2010; 27(2):95-101. DOI: 10.1007/s10014-010-0272-x. View

17.

PEIFFER J, Kleihues P . Hans-Joachim Scherer (1906-1945), pioneer in glioma research. Brain Pathol. 1999; 9(2):241-5. PMC: 8098443. DOI: 10.1111/j.1750-3639.1999.tb00222.x. View

18.

Ohgaki H, Kleihues P . Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007; 170(5):1445-53. PMC: 1854940. DOI: 10.2353/ajpath.2007.070011. View

19.

Choe G, Park J, Kremen T, Liau L, Vinters H, Cloughesy T . Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002; 8(9):2894-901. View

20.

Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko M . Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011; 28(2):115-23. DOI: 10.1007/s10014-011-0023-7. View